sephb4-hsa
Recombinant proteinexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2019 (NCT04091867)
Timeline
Indications
Mechanism of action
- Ephrin type-B receptor 4INHIBITOR
EPHB4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04486781 | Phase 2 | Dec 31, 2020 | Sarcoma Oncology Research Center, LLC, University of Southern California, Vasgene Therapeutics, Inc |
| NCT04091867 | Phase 1 | Oct 31, 2019 | University of Colorado, Denver, Vasgene Therapeutics, Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vasgene Therapeutics, Inc | For profit | 2 | 1 | 2 | 2019 |
| Sarcoma Oncology Research Center, LLC | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1